Product Description
Arhalofenate is also purported to have antiinflammatory activity through inhibition of interleukin-1β (IL-1β), as demonstrated in a monosodium urate murine air pouch model. Arhalofenate was first developed as an insulin sensitizer for type 2 diabetes mellitus. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982369/)
Mechanisms of Action: URAT1 Blocker
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: CymaBay
Company Location: NEWARK CA 94560
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Type 2 Diabetes
Phase 2: Type 2 Diabetes|Gout
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CB102-21425 | P2 |
Completed |
Gout |
2015-01-01 |
|
| CB102-21426 | P2 |
Completed |
Gout |
2014-12-01 |
|
| M102-21123 | P2 |
Completed |
Gout |
2012-02-01 |
|
| M102-21122 | P2 |
Completed |
Gout |
2011-11-01 |